XML 48 R27.htm IDEA: XBRL DOCUMENT
v2.4.0.6

Collaboration Arrangements (Details) (USD $) | 3 Months Ended | 9 Months Ended |  | 3 Months Ended | 9 Months Ended |  | 9 Months Ended |  | 3 Months Ended | 9 Months Ended |  | 3 Months Ended | 9 Months Ended |  | 9 Months Ended |  | 9 Months Ended | 3 Months Ended | 9 Months Ended |  | 1 Months Ended |  | 3 Months Ended | 9 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2012 | Sep. 30, 2011 | Dec. 31, 2011 | Sep. 30, 2012 GSK | Sep. 30, 2011 GSK | Sep. 30, 2012 GSK | Sep. 30, 2011 GSK | Sep. 30, 2012 VIBATIV | Sep. 30, 2012 VIBATIV Maximum | Sep. 30, 2012 Long-acting beta agonist (LABA) collaboration GSK product | Sep. 30, 2012 Long-acting beta agonist (LABA) collaboration LABA collaboration GSK | Sep. 30, 2011 Long-acting beta agonist (LABA) collaboration LABA collaboration GSK | Sep. 30, 2012 Long-acting beta agonist (LABA) collaboration LABA collaboration GSK | Sep. 30, 2011 Long-acting beta agonist (LABA) collaboration LABA collaboration GSK | Sep. 30, 2012 2004 Strategic alliance LAMA GSK | Sep. 30, 2012 2004 Strategic alliance MABA GSK | Sep. 30, 2011 2004 Strategic alliance MABA GSK | Sep. 30, 2012 2004 Strategic alliance MABA GSK product | Sep. 30, 2011 2004 Strategic alliance MABA GSK | Sep. 30, 2012 2004 Strategic alliance MABA containing '081 GSK | Sep. 30, 2012 2004 Strategic alliance MABA containing '081 - single-agent GSK | Sep. 30, 2012 2004 Strategic alliance MABA containing '081 - single-agent GSK Maximum | Sep. 30, 2012 2004 Strategic alliance MABA containing '081 - single-agent GSK Minimum | Sep. 30, 2012 2004 Strategic alliance MABA containing '081 - combination product GSK | Sep. 30, 2012 2004 Strategic alliance MABA containing additional MABA GSK product | Sep. 30, 2012 2004 Strategic alliance MABA containing additional MABA GSK Maximum | Sep. 30, 2012 2004 Strategic alliance MABA containing additional MABA - single-agent GSK | Sep. 30, 2012 2004 Strategic alliance MABA containing additional MABA - single-agent GSK Maximum | Sep. 30, 2012 2004 Strategic alliance MABA containing additional MABA - single-agent GSK Minimum | Sep. 30, 2012 2004 Strategic alliance MABA containing additional MABA - combination product GSK | Sep. 30, 2011 2004 Strategic alliance Non-license specific GSK | Sep. 30, 2011 2004 Strategic alliance Non-license specific GSK | Sep. 30, 2012 2004 Strategic alliance Non-license specific GSK | Aug. 31, 2012 Governance agreement Common stock GSK | Feb. 29, 2012 Governance agreement Common stock GSK | Nov. 30, 2011 Governance agreement Common stock GSK | Aug. 31, 2011 Governance agreement Common stock GSK | May 31, 2011 Governance agreement Common stock GSK | Feb. 28, 2011 Governance agreement Common stock GSK | May 16, 2012 Common stock purchase agreement Common stock GSK | Mar. 31, 2012 License, Development and Commercialization Agreement With Astellas VIBATIV Astellas | Sep. 30, 2011 License, Development and Commercialization Agreement With Astellas VIBATIV Astellas | Sep. 30, 2012 License, Development and Commercialization Agreement With Astellas VIBATIV Astellas | Sep. 30, 2011 License, Development and Commercialization Agreement With Astellas VIBATIV Astellas
Information related to collaboration arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum obligation for milestone payments to GSK |  |  |  |  |  |  |  |  |  |  |  | $ 220,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of combination products |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Period over which portion of potential milestone payments could be payable to GSK |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty rate for first level of annual global net sales (as a percent) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15.00% |  |  |  |  |  |  |  |  | 20.00% | 10.00% |  |  |  |  | 15.00% | 10.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty rate for combination products as a percentage of the rate applied to single products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 70.00% |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty rate for sales above first level of annual global net sales (as a percent) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5.00% |  |  |  |  |  |  |  | 7.50% |  |  |  |  |  | 10.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalties payable to Astellas |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.00% |
Amount of purchase agreements for pharmaceutical ingredient and raw materials |  |  |  |  |  |  |  |  |  |  | 6,200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount of purchase agreements for finished goods inventory |  |  |  |  |  |  |  |  |  |  | 4,200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchases of active pharmaceutical ingredient and other raw materials |  |  |  |  |  |  |  |  |  | 4,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Liability recorded due to termination agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150,000 |
Annual global sales level used to determine royalty rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,000,000,000 |  |  |  |  |  |  |  | 3,500,000,000 |  |  |  |  |  | 3,500,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of products which Company is obligated to use diligent efforts to discover after license of a program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of combination products to be developed and commercialized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential upfront license and milestone payments that Company could receive |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 125,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential upfront license and milestone payments that Company could receive in respect of combination medicines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 250,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments that Company could receive |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 129,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Agreement to issue stock, number of shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000,000 |  |  |  |
Agreement to issue stock, price per share |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 21.2887 |  |  |  |
Agreement to issue stock, total investment in the Company's stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 212,887,000 |  |  |  |
Entity's common stock information |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock for cash in private placement to a related party (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 316,334 | 88,468 | 58,411 | 102,466 | 261,299 | 152,278 |  |  |  |  |
Issuance of common stock for cash in private placement to a related party |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8,924,000 | 1,603,000 | 1,298,000 | 2,020,000 | 6,689,000 | 3,609,000 |  |  |  |  |
GSK Upfront License Fees, Milestone Payments and Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront License Fees |  |  |  |  |  | 41,000,000 |  | 41,000,000 |  |  |  | 10,000,000 |  |  |  |  | 5,000,000 | 6,000,000 |  | 6,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,000,000 |  |  |  |  |  |  |  |  |  |  |
Milestone Payments |  |  |  |  |  | 69,000,000 |  | 69,000,000 |  |  |  | 50,000,000 |  |  |  |  | 3,000,000 | 16,000,000 |  | 16,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  | 110,000,000 |  | 110,000,000 |  |  |  | 60,000,000 |  |  |  |  | 8,000,000 | 22,000,000 |  | 22,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,000,000 |  |  |  |  |  |  |  |  |  |  |
Term of royalty payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 years |
License, Development and Commercialization Agreement with Astellas |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront license, milestone and other fees received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 191,000,000 |
Net revenue recognized under the collaboration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue | 1,430,000 | 6,431,000 | 129,960,000 | 19,150,000 |  | 1,430,000 | 2,380,000 | 4,291,000 | 7,294,000 |  |  |  | 907,000 | 1,270,000 | 2,722,000 | 3,811,000 |  | 523,000 | 621,000 | 1,569,000 | 1,625,000 |  |  |  |  |  |  |  |  |  |  |  | 489,000 | 1,858,000 |  |  |  |  |  |  |  |  |  | 4,051,000 | 125,669,000 | 11,856,000
Recognition of remaining deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 125,819,000 |  | 125,819,000 |
Amortization of deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,244,000 |  | 9,731,000
Royalties from net sales of VIBATIV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 807,000 |  | 2,131,000
Proceeds from VIBATIV delivered to Astellas |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,171,000
Cost of VIBATIV delivered to Astellas |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (1,177,000)
Astellas-labeled product sales allowance |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (150,000) |  | (150,000) |
Deferred revenue, non-current | 5,790,000 |  | 5,790,000 |  | 122,017,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 130,000 |
Accounts payable | $ 4,757,000 |  | $ 4,757,000 |  | $ 5,813,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 20,000 |

X
- Definition Aggregate value of shares to be issued by the entity under the common stock purchase agreement. + References No definition available. + Details
Name: | thrx_AgreementToIssueSharesAggregateValue
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of shares to be issued by the entity under the common stock purchase agreement. + References No definition available. + Details
Name: | thrx_AgreementToIssueSharesNumberOfShares
Namespace Prefix: | thrx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Price per share for shares to be issued by the entity under the common stock purchase agreement. + References No definition available. + Details
Name: | thrx_AgreementToIssueSharesPricePerShare
Namespace Prefix: | thrx_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the number of structurally different product candidates which the entity is obligated to use diligent efforts to discover at its own cost after the collaborator licenses a program. + References No definition available. + Details
Name: | thrx_CollaborationArrangementObligationToDiscoverStructurallyDifferentProductsAfterLicense
Namespace Prefix: | thrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the rate of royalty payable to the counterparty pursuant to terms of termination agreement of a collaboration agreement. + References No definition available. + Details
Name: | thrx_CollaborativeAgreementTerminationRateOfRoyaltyPayable
Namespace Prefix: | thrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period for which of royalty is payable to the counterparty pursuant to terms of termination agreement of a collaboration agreement. + References No definition available. + Details
Name: | thrx_CollaborativeAgreementTerminationRoyaltyPayableTerm
Namespace Prefix: | thrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | thrx_CollaborativeArrangementAbstract
Namespace Prefix: | thrx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period within which a portion of the potential milestone payments could be payable. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementBeginningOfMilestonePaymentsPeriod
Namespace Prefix: | thrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the maximum obligation for milestone payments under a collaborative arrangement, if both a single-agent and a combination product or two different combination products are launched under the collaborative arrangement in multiple regions of the world. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementMaximumObligationForMilestonePayments
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the cumulative amount of milestone payments received under the collaborative arrangement. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementMilestonePaymentsReceived
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the number of combination products which are agreed to be developed and commercialized under the collaborative arrangement. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementNumberOfCombinationProductsToBeDevelopedAndCommercialized
Namespace Prefix: | thrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of combination products which may be launched under the collaborative arrangement. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementNumberOfCombinationProductsToBeLaunched
Namespace Prefix: | thrx_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents potential future revenue from upfront and milestone payments under a collaborative arrangement for programs with single-agent medicines. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementPotentialFutureRevenueFromUpfrontAndMilestonePaymentsCombinationAgentMedicines
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents potential future revenue from upfront and milestone payments under a collaborative arrangement for programs with single-agent medicines. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementPotentialFutureRevenueFromUpfrontAndMilestonePaymentsSingleAgentMedicines
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the amount of potential milestone payments that would be recognized as revenue under collaborative arrangements. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementPotentialFutureRevenuesFromMilestonePayments
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | thrx_CollaborativeArrangementRevenueAbstract
Namespace Prefix: | thrx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty rate for combination products as a percentage of the rate applicable for single products under a collaborative arrangement. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementRoyaltyRateCombinationProductsAsPercentageOfSingleProducts
Namespace Prefix: | thrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementRoyaltyRateDefinedLevelOne
Namespace Prefix: | thrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementRoyaltyRateDefinedLevelTwo
Namespace Prefix: | thrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the cumulative amount of upfront fees received under the collaborative arrangement. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementUpfrontFeesReceived
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the amount of the purchase agreements for finished goods inventory. + References No definition available. + Details
Name: | thrx_PurchaseAgreementsAmountForFinishedGoodsMaximum
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of the purchase agreements for the active pharmaceutical ingredient and raw materials being manufactured. + References No definition available. + Details
Name: | thrx_PurchaseAgreementsAmountForPharmaceuticalIngredientAndRawMaterials
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents purchases of ingredients and other raw materials by the entity during the period. + References No definition available. + Details
Name: | thrx_PurchasesOfIngredientsAndOtherRawMaterials
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The remaining amount of deferred revenue that was recognized as revenue during the period due do the termination of the agreement. Excludes any revenue recognized through recurring amortization of deferred revenue during the period. + References No definition available. + Details
Name: | thrx_RecognitionOfAllRemainingDeferredRevenue
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of the liability to customers attributable to sales allowances for governmental rebates and chargeback's, which was assumed and recorded upon the contract termination. + References No definition available. + Details
Name: | thrx_SalesAllowancesLiability
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of shares issued during the period as a result of private placement to a related party. + References No definition available. + Details
Name: | thrx_StockIssuedDuringPeriodSharesPrivatePlacementToRelatedParty
Namespace Prefix: | thrx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value stock issued during the period as a result of private placement to a related party, net of issuance cost. + References No definition available. + Details
Name: | thrx_StockIssuedDuringPeriodValuePrivatePlacementToRelatedParty
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the cumulative amount of total upfront fees and milestone payments received under the collaborative arrangement. + References No definition available. + Details
Name: | thrx_UpfrontAndMilestonePaymentsReceived
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the cumulative amount of upfront, milestone and other payments received under the collaborative arrangement. + References No definition available. + Details
Name: | thrx_UpfrontMilestoneAndOtherFeesReceived
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 + Details
Name: | us-gaap_AccountsPayableCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total costs related to goods produced and sold during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 2 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 + Details
Name: | us-gaap_CostOfGoodsSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section A -Paragraph 7, 8 -Chapter 3 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 48 -Paragraph 6 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a),(d)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_OtherSalesRevenueNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A -Subsection 1 + Details
Name: | us-gaap_RecognitionOfDeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_RevenueRecognitionAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_RoyaltyRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate selling price reductions recognized during an accounting period including, but not limited to, the sale of defective or nonconforming goods, a strategy to increase sales (generally over the short-term), move slow-moving items, develop distribution channels, or reward valuable customers. Allowances are a deduction from gross revenue in arriving at net revenue. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_SalesAllowancesGoods
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration